Give it a rest!

The MMR Vaccine:
• Albonico, H., Klein, P., et al. �The immunization campaign against measles, mumps and rubella�coercion leading to a realm of uncertainty: medical objections to a continued MMR immunization campaign in Switzerland.� JAM 1992; 9(1). [180 European medical doctors oppose the use of MMR.]
• Wakefield, A., et al. �Measles, mumps and rubella vaccine: through a glass, darkly.� Adverse Drug Reaction and Toxicologica Reviews 2000; 19(4):265-283.
• Templeton, S. �MMR vaccine should not have been licensed.� Sunday Herald (London: December 10, 2000). [Article]
• Petrovic, M., et al. �Second dose of measles, mumps, and rubella vaccine: questionnaire survey of health professionals.� British Medical Journal 2001; 322:82-85. [Doctors and nurses do not recommend it.]
• BBC News. �Why Japan stopped using MMR,� (February 8, 2002). www.news.bbc.co.uk/hi/english/world/asia-pacific/newsid_1808000/1808316.stm

The MMR (or Measles) Vaccine and Autism:

• Oleske, J. �Elevated rubeola [measles] titers in autistic children.� Abstract presented by D. Zecca and Dr. Graffino at an NIH meeting (September 23, 1997). As quoted by Richard Gallup in �Autism and autoimmunity.� www.chiroweb.com/archives/18/14/10.html (April 15, 2002.)
• Fudenberg, H.H. �Dialysable lymphocyte extract (DlyE) in infantile onset autism: a pilot study.� Biotherapy 1996; 9:143-147.
• Gupta, S. �Immunology and immunologic treatment of autism.� Proceedings of the National Autism Association, Chicago 1996: 455-460.
• Wakefield, A.J., et al. �Ileal-lymphoid-nodular hyperplasia, non-specific colitis, and pervasive developmental disorder in children.� Lancet 1998; 351:637-641.
• Yazbak, F.E. �Autism: Is there a vaccine connection? Part I. Vaccination after delivery.� 1999. www.garynull.com/documents/autism99b.htm
• Yazbak, F.E. �Autism: Is there a vaccine connection? Part II. Vaccination around pregnancy.� 1999. www.garynull.com/documents/autism99b2.htm
• Yazbak, F.E. �Autism: Is there a vaccine connection? Part III. Vaccination around pregnancy, the sequel.� 2000. www.garynull.com/documents/autism99b3.htm
• �Autism: Present Challenges, Future Needs�Why the Increased Rates?� Government Reform Committee Hearing, Washington, DC. (April 6, 2000.)
• �Autism: Why the Increased Rates? A One-Year Update.� Government Reform Committee Hearing, Washington, DC. (April 25-26, 2001.)
• �The Autism Epidemic: Is the NIH and CDC Response Adequate?� Government Reform Committee Hearing, Washington, DC. (April 18, 2002.)
• �The Status of Research into Vaccine Safety and Autism.� Government Reform Committee Hearing, Washington, DC. (June 19, 2002.)
• Kawashima, K., et al. �Detection and sequencing of measles virus from peripheral mononuclear cells from patients with inflammatory bowel disease and autism.� Digestive Diseases and Sciences (April 2000); 45:723-729.
• Reuters Medical News. �Measles persistence confirmed in some patients with IBD, autistic enterocolitis.� (June 20, 2000). www.id.medscape.com/reuters/prof/2000/06/06.20/20000620scie001.html
• Wakefield, A.J. et al. �Enterocolitis in children with developmental disorders.� American Journal of Gastroenterology 2000; 95(9):2154-2156.
• Wakefield, A., et al. �Measles, mumps and rubella vaccine: through a glass, darkly.� Adverse Drug Reaction and Toxicologica Reviews 2000; 19(4):265-283.
• Kiln MR, "Autism, inflammatory bowel disease, and MMR vaccine." Lancet 1998 May 2;351(9112):1358.
•  Selway, "MMR vaccination and autism 1998. Medical practitioners need to give more than reassurance." BMJ 1998 Jun 13;316(7147):1824.
•  Nicoll A, Elliman D, Ross E, "MMR vaccination and autism 1998," MJ 1998 Mar 7;316(7133):715-716.
•  Lindley K J, Milla PJ, "Autism, inflammatory bowel disease, and MMR vaccine."Lancet 1998 Mar 21;351(9106):907-908.
• Bedford H, et al, "Autism, inflammatory bowel disease, and MMR vaccine." Lancet 1998 Mar 21;351(9106):907.
• Vijendra K. Singh, Sheren X. Lin, and Victor C. Yang, "Serological Association of Measles Virus and Human Herpesvirus-6 with Brain Autoantibodies in Autism," Clinical Immunology and Immunopathology, Oct 1998, Vol. 89, No. 1, p 105-108.

Figure 1:

Copyright © 2002, NZM.
All Rights Reserved.

Severe Afflictions affecting nearly every body system -- blood, lymphatic, digestive, cardiovascular, immune, nervous, respiratory, and sensory -- have been linked to the MMR vaccine. Source: Multiple studies; The vaccine manufacturer; Physician's Desk Reference (PDR); 55th edition, 2001, p. 1954.

Excerpts from New MMR Booklet

Vitamin A Improves Measles Complication Rates:
• Clinical Infectious Diseases (September 1994), p. 493.
• Oomen, APC. �Clinical experience of hypovitamine A.� Fed Proc 1958; 17:111-124.
• Wilson, D., et al. �Infection and nutritional status. III. The effect of measles on nitrogen metabolism in children.� American Journal of Clinical Nutrition 1961; 9:154-58.
• Sommer, A., et al. �Increased risk of respiratory disease and diarrhea in children with pre-existing mild vitamin A deficiency.� American Journal of Clinical Nutrition 1984; 40:1090-95.
• Sommer, A., et al. �Impact of vitamin A supplementation on childhood mortality: a randomized clinical trial.� Lancet 1986; 1:1169-73.
• Barclay, A.J.G., et al. �Vitamin A supplements and mortality related to measles: a randomised clinical trial.� British Medical Journal (January 31, 1987), pp. 294-96.
• Keusch, G.T. �Vitamin A supplements�too good to be true.� New England Journal of Medicine (October 4, 1990), p. 986.
• Frieden, T.R., et al. �Vitamin A levels and severity of measles: New York City.� Am J Dis Child 1992; 146:182-86.
• Pediatric Nursing (September/October 1996).

Fever Reducers (aspirin) Prolong Measles Complication Rates:

• Witsenburg, B.C. �Measles mortality and therapy,� pp. 26-27. From an abstract of a 1967-1968 measles epidemic study conducted in Ghana.
• Ahmady, A.S., et al. �The adverse effects of antipyretics in measles.� Indian Pediatrics (January 1981), pp. 49-52.

The Measles (and MMR) Vaccine and Neurological Disorders
(Including Central Nervous System Damage, subacute sclerosing panencephalitis [brain disease], and Guillain-Barre' syndrome [paralysis]):

• Schneck, S.A. �Vaccination with measles and central nervous system disease.� Neurology 1968; 18 (Part 2):79-82.
• Jabbour, J.T., et al. �Epidemiology of subacute sclerosing panencephalitis (SSPE).� Journal of the American Medical Association 1972; 220:959-62.
• Belgamwar, R.B., et al. �Measles, mumps, rubella vaccine induced subacute sclerosing panencephalitis.� Journal of the Indian Medical Association 1997; 95(11):594.
• Landrigan, P.J., et al. �Neurological disorders following live measles-virus vaccination.� Journal of the American Medical Association 1973; 223 (13):1459-62.
• Miller, C.L. Lancet (September 17, 1983).
• Beale, A.J. �Measles vaccines.� Proceedings of the Royal Society of Medicine 1974; 67:1116-1119.
• Roden, A.T. �Fits following immunization.� Proceedings of the Royal Society of Medicine 1974; 67:24.
• Jagdis, F., et al. �Encephalitis after administration of live measles vaccine.� Journal of the Canadian Medical Association (April 19, 1975); 112(8):972-75.
• Hirayama, M. �Measles vaccines used in Japan.� Reviews of Infectious Diseases 1983; 5:495-503.
• Pollock, T.M., et al. �A 7-year survey of disorders attributed to vaccination in Northwest Thames Region.� Lancet 1983; 1:753-57.
• Jorch, G. et al. �Coincidence of virus encephalitis and measles-mumps vaccination.� Monatsschr Kinderheilkd 1984; 132(5):299-300.
• Martinon-Torres, F., et al. �Self-limited acute encephalopathy related to measles component of viral triple vaccine.� Rev Neurol (May 1-15, 1999); 28(9):881-82.
• Grose, C., et al. �Guillain-Barr� syndrome following administration of live measles vaccine.� American Journal of Medicine 1976; 60:441-43.
• Norrby, R. �Polyradiculitis in connection with vaccination against morbilli, parotitis and rubella.� Lakartidningen 1984; 81:1636-37.
• Morris, K., et al. �Guillain-Barr� syndrome after measles, mumps, and rubella vaccine.� Lancet 1994; 343:60.

The Measles (and MMR) Vaccine and Serious Blood Disorders:

• Oski, F.A. and Naiman, J.L. �Effect of live measles vaccine on the platelet count.� New England Journal of Medicine 1966; 265:352-56.
• Bottiger, M., et al. �Swedish experience of two dose vaccination programme aiming at eliminating measles, mumps, and rubella.� British Medical Journal 1987; 295:1264-67.
• Koch, J. et al. �Adverse events temporally associated with immunizing agents�1987 report.� Canada Diseases Weekly Report 1989; 15:151-58.
• Fescharek, R., et al. �Measles-mumps vaccination in the FRG: an empirical analysis after 14 years of use. II. Tolerability and analysis of spontaneously reported side effects.� Vaccine 1990; 8:446-56.
• Nieminen, U., et al. �Acute thrombocytopenic purpura following measles, mumps and rubella vaccination: A report on 23 patients.� Acta Paediatrica 1993; 82:267-70.
• 146. Farrington, P., et al. �A new method for active surveillance of adverse events from diphtheria/tetanus/pertussis and measles/mumps/rubella vaccines.� Lancet 1995; 345: 567-69.
• Jonville-Bera, A.P., et al. �Thrombocytopenic purpura after measles, mumps, and rubella vaccination: a retrospective survey by the French Regional Pharmacovigilance Centres and Pasteur-Merieux Serums et Vaccins.� Pediatr Infect Dis J 1996; 15:44-48.
• Beeler, J. et al. �Thrombocytopenia after immunization with measles vaccines: review of the Vaccine Adverse Events Reporting Systerm (1990-1994).� Pediatr Infect Dis J 1996; 15:88-90.

The Measles (and MMR) Vaccine and Sensory Impairments
(Including Eye Disorders and Hearing Loss):

• Kazarian, E.L., et al. �Optic neuritis complicating measles, mumps, and rubella vaccination.� American Journal of Ophthalmology 1978; 86:544-47.
• Marshall, G.S., et al. �Diffuse retinopathy following measles, mumps, and rubella vaccination.� Pediatrics 1985; 76:989-991.
• Brodsky, L., et al. �Sensorineural hearing loss following live measles virus vaccination.� International Journal of Pediatric Otorhinolaryngology 1985; 10:159-63.
• Nabe-Nielsen, J., et al. �Unilateral deafness as a complication of the mumps, measles, and rubella vaccination.� British Medical Journal 1988; 297:489.
• Hulbert, T.V., et al. �Bilateral hearing loss after measles and rubella vaccination in an adult.� New England Journal of Medicine 1991; 325:134.
• Stewart, B.J.A., et al. �Reports of sensorineural deafness after measles, mumps, and rubella immunisation.� Archives of Diseases of Childhood 1993; 69:153-54.

The Measles (and MMR) Vaccine and Immune System Damage
(Other Than Autism):

• Hirsch, R.L., et al. �Measles virus vaccination of measles seropositive individuals suppresses lymphocyte proliferation and chemotactic factor production.� Clinical Immunology and Immunopathology 1981; 21:341-50.
• Nicholson, J.K.A., et al. �The effect of measles-rubella vaccination on lymphocyte populations and subpopulations in HIV-infected and healthy individuals.� Journal of Acquired Immune Deficiency Syndromes 1992; 5:528-537.

The Measles (and MMR) Vaccine and Bowel Disease:

• Thompson, N.P., Wakefield, A.J, et al. �Is measles vaccination a risk factor for inflammatory bowel disease?� Lancet 1995; 345:1071-1074.
• Barton, J.R., et al. �Incidence of inflammatory bowel disease in Scottish children between 1968 and 1983: marginal fall in ulcerative colitis; three-fold rise in Crohn�s disease.� Gut 1989; 30:618-622.
• Whelan, G. �Epidemiology of inflammatory bowel disease.� Med Clin N Am 1990; 74:1-12.
• Ekbom, A., et al. �The role of perinatal measles infection in the aetiology of Crohn�s disease: a population-based epidemiological study.� Lancet 1994; 334:508-510.
• Miyamoto, H., et al. �Detection of immunoreactive antigen with monoclonal antibody to measles virus in tissue from patients with Crohn�s disease.� Journal of Gastroenterology 1995; 30:28-33.
• Wakefield, A.J., et al. �Evidence of persistent measles virus infection in Crohn�s disease.� Journal of Medical Virology 1993; 39:345-53.
• Wakefield, A.J., et al. �Crohn�s disease: pathogenesis and persistent measles virus infection.� Gastroenterology 1995; 108:911-916.
• Lewin, J., et al. �Confirmation of persistent measles virus infection of intestinal tissue by immunogold electron microscopy.� Gut 1995; 36:564-69.

The Measles (and MMR) Vaccine and Severe Allergic Reactions:

• Aukrust, L., et al. �Severe hypersensitivity or intolerance reactions to measles vaccine in six children: clinical and immunological studies.� Allergy 1980; 35(7):581-87.
• McEwen, J. �Early-onset reaction after measles vaccination: further Australian reports.� Medical Journal of Australia 1983; 2:503-505.
• Koch, J., et al. �Adverse events temporally associated with immunizing agents�1987 report.� Canada Diseases Weekly Report 1989; 15:151-58.
• Kelso, J.M., et al. �Anaphylaxis to measles, mumps, and rubella vaccine mediated by IgE to gelatin.� J Allergy Clin Immunol 1993; 91:867-72.
• Sakaguchi, M., et al. �IgE antibody to gelatin in children with immediate-type reactions to measles and mumps vaccines.� J Allergy Clin Immunol 1995; 96:563-65.

The Measles Vaccine and "Atypical" Measles:

• Cherry, J.D. �The �new� epidemiology of measles and rubella.� Hospital Practice (July 1980), pp. 53-54.
• Fulginiti, V.A., et al. �Altered reactivity to measles virus; atypical measles in children previously immunized with inactivated measles virus vaccines.� Journal of the American Medical Association 1967; 202:1075.
• Martin, D.B., et al. �Atypical measles in adolescents and young adults.� Annals of Internal Medicine 1979; 90:877.
• Gold, E. �Current progress in measles eradication in the United States.� Infect Med 1997; 14(4):297-300, 310.
• Nichols, E.M. �Atypical measles: a continuing problem.� American Journal of Public Health 1979; 69(2):160-62.
• Scott, T.F., et al. �Reactions to live-measles-virus vaccine in children previously inoculated with killed-virus vaccine.� New England Journal of Medicine 1967; 277(5):248-251.
• Cherry, J.D., et al. �Atypical measles in children previously immunized with attenuated measles virus vaccines.� Pediatrics 1972; 50(5).
• St. Geme, J.W., et al. �Exaggerated natural measles following attenuated virus immunization.� Pediatrics 1976; 57:148-150.
• �Atypical measles syndrome.� Lancet 1979, pp. 962-963.

The Measles Death Rate Tumbled Prior to the Measles Vaccine:

• Alderson, Michael. International Mortality Statistics (Washington, DC: Facts on File, 1981), pp. 182-183.

The Measles Vaccine is Ineffective
(Outbreaks Often Occur Among Highly, or Fully, Vaccinated Populations):

• FDA. �FDA workshop to review warnings, use instructions, and precautionary information [on vaccines].� (Rockland, Maryland: FDA, September 18, 1992), p. 27.
• Faich, G.A., et al. �Measles outbreak in Rhode Island.� Public Health Report 1981 May-June; 96(3):264-266.
• CDC. MMWR (February 1, 1985).
• CDC. MMWR (June 1984).
• CDC. MMWR (June 6, 1987).
• Gustafson, T. �Measles outbreak in a fully immunized secondary school population.� New England Journal of Medicine 1987; 316:771-74.
• Markowitz, L.E., et al. �Patterns of transmission in measles outbreaks in the United States, 1985-1986.� New England Journal of Medicine 1989; 320:75-81.
• Robertson, S.E., et al. �A million dollar measles outbreak: epidemiology, risk factors, and a selective revaccination strategy.� Public Health Reports (January-February 1992), p. 24.
• Edmonson, M.B., et al. �Mild measles and secondary vaccine failure during a sustained outbreak in a highly vaccinated population.� Journal of the American Medical Association 1990; 263:2467-71.
• Minnesota Department of Health. �Measles summary, 1987.�
• CDC. �Measles.� MMWR 1989; 38:329-330.
• CDC. �Measles�Quebec.� MMWR 1989; 38:329-30.
• CDC. �Measles�United States, 1990. MMWR 1991; 40(2):369.
• CDC. �U.S. Childhood Immunization Update: Measles.� (March 1997).
• CDC. �Measles�United States, 1999.� MMWR 2000; 49(25): 557-560.

Natural Immunity is Superior:

• CDC. �Babies of vaccinated moms more susceptible to measles.� Pediatrics (November 1999).
• �Natural immunity to measles yields greater neutralizing capacity than vaccination.� Journal of Medical Virology 2000; 62:91-98.

The Measles Vaccine Alters the Epidemiology of the Disease (It Causes Higher Rates of Measles in High-Risk Groups):

• Cherry, J.D. �The �new� epidemiology of measles and rubella.� Hospital Practice (July 1980), p. 51.
• Macgregor, J.D., et al. �Epidemic measles in Shetland during 1977 and 1978.� British Medical Journal 1981; 282(6262):434-436.
• Gold, E. �Current progress in measles eradication in the United States.� Infect Med 1997; 14(4):297-300, 310.
• CDC. �Measles�United States, 1999.� MMWR 2000; 49(25): 557-560.

Authorities Experimented on Children with a Proven Deadly Measles Vaccine:

• Sabin, A.B., et al. �Successful immunization of children with and without maternal antibody by aerosolized measles vaccine. I. Different results with undiluted human diploid cell and chick embryo fibroblast vaccines.� JAMA 1983; 249:2651-62.
• Sabin, A.B., et al. �Successful immunization of children with and without maternal antibody by aerosolized measles vaccine. II. Vaccine comparisons and evidence for multiple antibody response. JAMA 1984; 251:2363-71.
• Whittle, H.C., et al. �Immunisation of 4-6 month old Gambian infants with Edmonston-Zagreb measles vaccine.� Lancet 1984; ii:834-37.
• Whittle, H., et al. �Trial of high-dose Edmonston-Zagreb measles vaccine in The Gambia: antibody response and side-effects.� Lancet 1988; ii:811-814.
• Aaby, P., et al. �Trial of high-dose Edmonston-Zagreb measles vaccine in Guinea-Bissau: protective efficacy.� Lancet 1988; i:809-811.
• Garenne, M., et al. �Child mortality after high-titre measles vaccines: prospective study in Senegal.� Lancet 1991; 338:903-907.
• Whittle, H.C. �Effect of dose and strain of vaccine on success of measles vaccination of infants aged 4-5 months.� Lancet 1988; i:963-66.
• Khanum, S., et al. �Comparison of Edmonston-Zagreb and Schwartz strains of measles vaccine given by aerosol or subcutaneous injection.� Lancet 1987; i:150-53.
• Tidjani, O., et al. �Serological effects of Edmonston-Zagreb, Schwartz, and AIK-C measles vaccine strains given at ages 4-5 or 8-10 months.� Lancet 1989; ii:1357-60.
• Markowitz, L.E., et al. �Immunization of six-month-old infants with different doses of Edmonston-Zagreb and Schwartz measles vaccines.� New England Journal of Medicine 1990; 332:580-87.
• Awadu, K.O. Outrage! How Babies Were Used as Guinea Pigs in an L.A. County Vaccine Experiment. (Long Beach, CA: Conscious Rastra Press, 1996).